<DOC>
	<DOCNO>NCT00002014</DOCNO>
	<brief_summary>To determine safety tolerance various combination zidovudine ( AZT ) didanosine ( ddI ) administer concurrently . To determine pharmacokinetics concurrent AZT ddI administer orally . To evaluate antiviral , immunologic virologic effect AZT ddI administer concurrently .</brief_summary>
	<brief_title>A Phase I Study Evaluate Pharmacokinetics , Safety Antiviral Effects Concurrent Administration Zidovudine ( AZT ) 2 ' 3'-Dideoxyinosine ( ddI ) Patients With Human Immunodeficiency Virus ( HIV )</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Didanosine</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Acyclovir exceed two 14day course therapy trial . Discontinue ddI receive acyclovir . Patients must follow : Positive HIV antibody use federally license ELISA test kit . CD4 count &lt; 400 two consecutive visit within one month prior entry . Prior Medication : Allowed : Zidovudine ( AZT ) treat less 120 day . Pharmacologic dos steroid give management Pneumocystis carinii pneumonia ( PCP ) ( exceed 21 day ) . Exclusion Criteria Coexisting Condition : Patients follow condition symptom exclude : Visceral progressive Kaposi 's sarcoma ( KS ) ( define &gt; 10 new lesion thirty day prior entry ) patient require chemotherapy radiation therapy Kaposi 's sarcoma . Other concurrent neoplasm basal cell carcinoma skin situ carcinoma cervix . Malabsorption define persistent diarrhea ( &gt; 4 stools/day four week ) unresponsive antidiarrheal agent . Opportunistic infection require maintenance therapy . History Central Nervous System opportunistic infection ( e.g. , toxoplasmosis , cryptococcosis ) . History seizure disorder . Prior history pancreatitis . History peripheral neuropathy significant sign symptom neurological disease . Examinations peripheral neuropathy ass change extremity . Clinically significant hyperuricemia ( tophaceous gout , urate nephropathy ) . History cardiomyopathy . Concurrent Medication : Excluded : Intravenous pentamidine . Intravenous trimethoprim / sulfamethoxazole . Alcohol . Suppressive acyclovir therapy ( see Inclusion Medications ) . Allopurinol . Probenecid . Isoniazid ( INH ) . Dipyridamole . Concurrent Treatment : Excluded : Radiation therapy Kaposi 's sarcoma . Patients follow exclude : Zidovudine ( AZT ) intolerance evidence inability tolerate least 600 mg AZT daily . Previously intolerant didanosine ( ddI ) evidence peripheral neuropathy seizure pancreatitis gastrointestinal toxicity hematologic toxicity . Diseases condition list Patient Exclusion Coexisting Conditions . Prior Medication : Excluded : Zidovudine ( AZT ) &gt; 120 day . Dideoxycytidine ( ddC ) . Excluded within 30 day study entry : Antiretroviral therapy . Immunomodulators . Biological response modifier . Cytotoxic chemotherapy Kaposi 's sarcoma . Excluded within 60 day study entry : Ribavirin . Prior Treatment : Excluded within 2 week study entry : Transfusions . Excluded within 30 day study entry : Radiation therapy Kaposi 's sarcoma . Active substance abuse would impair compliance study procedure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 1991</verification_date>
	<keyword>Didanosine</keyword>
	<keyword>Drug Evaluation</keyword>
	<keyword>Zidovudine</keyword>
</DOC>